Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nader Moazami

Thoracic Surgery (Cardiothoracic Vascular Surgery) Minneapolis, MN Medical Doctor

NPI 1356367676 CMS profile 60789

920 E 28Th St, Ste. 610, Minneapolis, MN 55407

Open in the dashboard

General payments

$28,485

59 records reported · program years 2019–2025

Research payments

$10,225

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$227,541 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Nader Moazami of Minneapolis, MN is reported in the CMS Open Payments database as having received $28,485 across 59 general payments and $10,225 in research payments paid to them. Separately, studies naming them as principal investigator received $227,541 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,097 5
2025 Research $500 1
2024 General $2,965 7
2024 Research $500 2
2023 General $1,412 6
2023 Research $1,500 5
2022 General $3,488 8
2022 Research $500 2
2021 General $4,725 7
2021 Research $2,250 4
2020 General $4,307 4
2020 Research $1,600 2
2019 General $7,491 22
2019 Research $3,375 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nader Moazami
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Nader Moazami were reported at $4,097. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Nader Moazami Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $7,491 $886 $178–$3,167 $163
2020 $4,307 $341 $108–$1,605 $114
2021 $4,725 $453 $125–$1,886 $132
2022 $3,488 $695 $180–$2,566 $149
2023 $1,412 $745 $205–$2,662 $160
2024 $2,965 $799 $214–$2,967 $164
2025 $4,097 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $11,649 25 payments
  2. Medtronic, Inc. $9,338 17 payments
  3. Octapharma USA, Inc. $4,000 1 payment
  4. Abbott Laboratories $2,600 7 payments
  5. XVIVO Perfusion Inc. $369 2 payments
  6. Paragonix Technologies, Inc. $280 2 payments
  7. Abiomed $177 2 payments
  8. Hikma Pharmaceuticals USA $38 2 payments
  9. One Lambda, Inc. $34 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $20,863 24 payments
  2. Honoraria $4,000 1 payment
  3. Food and Beverage $2,156 28 payments
  4. Travel and Lodging $1,442 5 payments
  5. Gift $24 1 payment
Products named General payments · program years 2019–2025
  1. HeartWare HVAD Ventricular Assist Devices $9,872 11 payments
  2. FIBRYGA & BALFAXAR $4,000 1 payment
  3. HeartWare HVAD Ventricular Assist Devices $2,700 4 payments
  4. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $2,570 6 payments
  5. XVIVO Perfusion System (XPS) $281 1 payment
  6. LungGuard $280 2 payments
  7. BaroGuard $280 2 payments
  8. LiverGuard $280 2 payments
  9. SherpaPak $280 2 payments
  10. PancreasPak $280 2 payments
  11. Other $216 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $5,250 14 payments
  2. Medtronic Vascular, Inc. $4,975 3 payments

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$47,932

Medicare's payments for the services billed

Medicare patients

17

Average age 62

Services billed

41

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Chronic kidney disease 75%
Atrial fibrillation 71%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record